Difference between revisions of "Octreotide (Sandostatin)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_inj.pdf Octreotide (Sandostatin) package insert]</ref><r...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_inj.pdf Octreotide (Sandostatin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/octreotide.pdf Octreotide (Sandostatin) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_inj.pdf Octreotide (Sandostatin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/octreotide.pdf Octreotide (Sandostatin) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: SC, IV |
| − | <br>Extravasation: | + | <br>Extravasation: no information |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
Revision as of 20:56, 23 February 2012
General information
Class/mechanism: Long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.[1][2]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Octreotide (Sandostatin) patient drug information (Chemocare)[3]
- Octreotide (Sandostatin) patient drug information (UpToDate)[4]